ENC1

Summary

ENC1 (ectodermal-neural cortex 1, HGNC:3345) is a protein-coding gene on chromosome 5q13.3, encoding Ectoderm-neural cortex protein 1 (O14682). Actin-binding protein involved in the regulation of neuronal process formation and in differentiation of neural crest cells.

This gene encodes a member of the kelch-related family of actin-binding proteins. The encoded protein plays a role in the oxidative stress response as a regulator of the transcription factor Nrf2, and expression of this gene may play a role in malignant transformation. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

Source: NCBI Gene 8507 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 40 total
• MANE Select transcript: NM_003633

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3345
Approved symbol	ENC1
Name	ectodermal-neural cortex 1
Location	5q13.3
Locus type	gene with protein product
Status	Approved
Aliases	PIG10, ENC-1, TP53I10, KLHL37
Ensembl gene	ENSG00000171617
Ensembl biotype	protein_coding
OMIM	605173
Entrez	8507

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 18 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000302351, ENST00000508331, ENST00000509127, ENST00000509284, ENST00000510316, ENST00000618628, ENST00000651128, ENST00000875692, ENST00000875693, ENST00000875694, ENST00000875695, ENST00000875696, ENST00000875697, ENST00000875698, ENST00000875699, ENST00000875700, ENST00000875701, ENST00000875702, ENST00000928979

RefSeq mRNA: 4 — MANE Select: NM_003633 NM_001256574, NM_001256575, NM_001256576, NM_003633

CCDS: CCDS4021, CCDS58958

Canonical transcript exons

ENST00000302351 — 3 exons

Exon	Start	End
ENSE00001128061	74627409	74629992
ENSE00001171615	74634684	74636498
ENSE00003244649	74640307	74640728

Expression profiles

Bgee: expression breadth ubiquitous, 280 present calls, max score 99.88.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 46.1902 / max 1865.4284, expressed in 1690 samples.

FANTOM5 promoters (19 alternative TSS)

Promoter ID	TPM avg	Samples expressed
62078	30.0581	1600
62075	11.2163	1568
62077	1.6111	344
62076	1.0718	289
62079	0.4183	115
62081	0.3049	131
62082	0.2525	86
62087	0.2428	88
62074	0.1770	80
62073	0.1617	66

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
Brodmann (1909) area 10	UBERON:0013541	99.88	gold quality
frontal pole	UBERON:0002795	99.86	gold quality
middle temporal gyrus	UBERON:0002771	99.67	gold quality
ganglionic eminence	UBERON:0004023	99.54	gold quality
orbitofrontal cortex	UBERON:0004167	99.41	gold quality
Brodmann (1909) area 46	UBERON:0006483	99.25	gold quality
superior frontal gyrus	UBERON:0002661	99.21	gold quality
CA1 field of hippocampus	UBERON:0003881	99.20	gold quality
ventricular zone	UBERON:0003053	99.02	gold quality
parietal lobe	UBERON:0001872	98.92	gold quality
postcentral gyrus	UBERON:0002581	98.76	gold quality
cortical plate	UBERON:0005343	98.35	gold quality
Brodmann (1909) area 23	UBERON:0013554	98.32	gold quality
entorhinal cortex	UBERON:0002728	98.20	gold quality
prefrontal cortex	UBERON:0000451	98.16	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	98.13	gold quality
frontal lobe	UBERON:0016525	97.92	gold quality
frontal cortex	UBERON:0001870	97.91	gold quality
neocortex	UBERON:0001950	97.69	gold quality
occipital lobe	UBERON:0002021	97.69	gold quality
cerebral cortex	UBERON:0000956	97.67	gold quality
Brodmann (1909) area 9	UBERON:0013540	97.64	gold quality
middle frontal gyrus	UBERON:0002702	97.56	gold quality
adult organism	UBERON:0007023	97.52	gold quality
primary visual cortex	UBERON:0002436	97.10	gold quality
cingulate cortex	UBERON:0003027	96.76	gold quality
embryo	UBERON:0000922	96.74	gold quality
anterior cingulate cortex	UBERON:0009835	96.74	gold quality
temporal lobe	UBERON:0001871	96.64	gold quality
Ammon’s horn	UBERON:0001954	96.37	gold quality

Single-cell (SCXA)

Detected in 11 experiment(s), a significant marker in 11.

Experiment	Marker?	Max mean expression
E-HCAD-30	yes	2192.51
E-HCAD-56	yes	1174.27
E-GEOD-109979	yes	1099.45
E-MTAB-8894	yes	1082.84
E-HCAD-25	yes	913.48
E-HCAD-5	yes	807.07
E-MTAB-10018	yes	173.85
E-HCAD-35	yes	58.25
E-CURD-114	yes	10.41
E-ANND-3	yes	7.09
E-ENAD-27	yes	6.68

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CTNNB1, NFE2L2, TCF4, TCF7L2

miRNA regulators (miRDB)

143 targeting ENC1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-4648	99.91	67.00	710

Literature-anchored findings (GeneRIF, showing 12)

• results suggest that upregulation of ENC-1 contributes to the development of HCL and provides new information on the possible dysregulation of ENC-1 including expression of a novel antisense gene, ENC-1AS (PMID:15459180)
• NRP/B enhances oxidative stress responses in breast cancer cells via the Nrf2 pathway, identifying a novel role of nuclear matrix protein(s) in oxidative stress responses. (PMID:17875699)
• NRP/B mutations impair Nrf2-dependent NQO1 induction in primary brain tumors. (PMID:18981988)
• ENC1 functions as a negative regulator of Nrf2 through suppressing Nrf2 protein translation. (PMID:19424503)
• ENC1 interacts with the phosphorylated p62 to impair autophagic degradation of mutant huntingtin protein aggregates. (PMID:26637326)
• we identified ENC1 and UNC5C as genes with convergent genetic, epigenetic, and transcriptomic evidence supporting a potential role in the dissociation of cognition and neuropathology in an aging population. (PMID:28441426)
• The low expression of ENC1 was associated with favorable prognosis in ovarian cancer patients. And the knockdown of ENC1 can significantly inhibit ovarian cancer cell proliferation, migration, and invasion. (PMID:30125994)
• Ectodermal-neural cortex 1 as a novel biomarker predicts poor prognosis and induces metastasis in breast cancer by promoting Wnt/beta-catenin pathway. (PMID:32618411)
• Ectodermalneural cortex 1 affects the biological function of lung cancer through the MAPK pathway. (PMID:33693958)
• Aberrant super-enhancer-driven oncogene ENC1 promotes the radio-resistance of breast carcinoma. (PMID:34362881)
• The emerging role of ectodermal neural cortex 1 in cancer. (PMID:38177640)
• Comprehensive pan-cancer analysis reveals ENC1 as a promising prognostic biomarker for tumor microenvironment and therapeutic responses. (PMID:39455818)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	enc1	ENSDARG00000035398
mus_musculus	Enc1	ENSMUSG00000041773
rattus_norvegicus	Enc1	ENSRNOG00000016541
drosophila_melanogaster	gprs	FBGN0024232

Paralogs (2): KLHL25 (ENSG00000183655), BTBD17 (ENSG00000204347)

Protein

Protein identifiers

Ectoderm-neural cortex protein 1 — O14682 (reviewed: O14682)

Alternative names: Kelch-like protein 37, Nuclear matrix protein NRP/B, p53-induced gene 10 protein

All UniProt accessions (3): D6R9D7, O14682, Q53XS2

UniProt curated annotations — full annotation on UniProt →

Function. Actin-binding protein involved in the regulation of neuronal process formation and in differentiation of neural crest cells. Down-regulates transcription factor NF2L2/NRF2 by decreasing the rate of protein synthesis and not via a ubiquitin-mediated proteasomal degradation mechanism.

Subunit / interactions. Binds to RB1. Hypophosphorylated RB1 associates with ENC1 during neuronal differentiation, while hyperphosphorylated RB1 associates with ENC1 in undifferentiating cells. Part of a complex that contains CUL3, RBX1 and ENC1. Interacts indirectly with KEAP1.

Subcellular location. Nucleus matrix. Cytoplasm. Cytoskeleton.

Tissue specificity. Detected in fetal brain tissue, moderate expression in fetal heart, lung and kidney. Highly expressed in adult brain, particularly high in the hippocampus and amygdala, and spinal cord. Detectable in adult pancreas. May be down-regulated in neuroblastoma tumors.

Post-translational modifications. Ubiquitinated by E3 ubiquitin ligase complex formed by CUL3 and RBX1 and probably targeted for proteasome-independent degradation. Quinone-induced oxidative stress increases its ubiquitination.

Induction. By p53/TP53.

Isoforms (2)

UniProt ID	Names	Canonical?
O14682-1	1	yes
O14682-2	2

RefSeq proteins (4): NP_001243503, NP_001243504, NP_001243505, NP_003624* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000210	BTB/POZ_dom	Domain
IPR006652	Kelch_1	Repeat
IPR011333	SKP1/BTB/POZ_sf	Homologous_superfamily
IPR011705	BACK	Domain
IPR015915	Kelch-typ_b-propeller	Homologous_superfamily
IPR017096	BTB-kelch_protein	Family
IPR030562	ENC1_BTB_POZ_dom	Domain
IPR047097	ENC1_BACK	Domain

Pfam: PF00651, PF01344, PF07707, PF24681

UniProt features (18 total): sequence conflict 8, repeat 6, chain 1, domain 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O14682-F1	88.22	0.62

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 450 (showing top): GSE45365_NK_CELL_VS_CD11B_DC_DN, GSE45365_NK_CELL_VS_BCELL_UP, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_NEUROGENESIS, GOBP_NEGATIVE_REGULATION_OF_TRANSLATION, RODRIGUES_NTN1_TARGETS_DN, GOBP_TRANSLATION, GOBP_POST_TRANSCRIPTIONAL_REGULATION_OF_GENE_EXPRESSION

GO Biological Process (7): nervous system development (GO:0007399), proteasomal ubiquitin-independent protein catabolic process (GO:0010499), positive regulation of neuron projection development (GO:0010976), protein ubiquitination (GO:0016567), negative regulation of translation (GO:0017148), obsolete proteolysis involved in protein catabolic process (GO:0051603), regulation of primary metabolic process (GO:0080090)

GO Molecular Function (2): actin binding (GO:0003779), protein binding (GO:0005515)

GO Cellular Component (8): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytoskeleton (GO:0005856), nuclear matrix (GO:0016363), Cul3-RING ubiquitin ligase complex (GO:0031463), neuronal cell body (GO:0043025)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
nuclear lumen	2
system development	1
proteasomal protein catabolic process	1
regulation of neuron projection development	1
neuron projection development	1
positive regulation of cell projection organization	1
protein modification by small protein conjugation	1
translation	1
regulation of translation	1
negative regulation of gene expression	1
negative regulation of protein metabolic process	1
regulation of metabolic process	1
primary metabolic process	1
cytoskeletal protein binding	1
binding	1
chromosome	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
intracellular membraneless organelle	1
cullin-RING ubiquitin ligase complex	1
somatodendritic compartment	1
cell body	1

Protein interactions and networks

STRING

1008 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ENC1	HEXB	P07686	912
ENC1	OGA	O60502	650
ENC1	SNX33	Q8WV41	642
ENC1	PLAGL2	Q9UPG8	500
ENC1	GM2A	P17900	492
ENC1	LARS1	Q9P2J5	490
ENC1	GPR85	P60893	483
ENC1	SQSTM1	Q13501	476
ENC1	RAG1	P15918	474
ENC1	TM9SF4	Q92544	473
ENC1	SOX15	P35717	456
ENC1	BRD4	O60885	445
ENC1	TBR1	Q16650	437
ENC1	RBBP8NL	Q8NC74	424
ENC1	ZIC1	Q15915	414

IntAct

39 interactions, top by confidence:

A	B	Type	Score
KLHL25	ENC1	psi-mi:“MI:0914”(association)	0.640
CUL3	ENC1	psi-mi:“MI:0914”(association)	0.640
KLHL9	ENC1	psi-mi:“MI:0914”(association)	0.640
ENC1	SQSTM1	psi-mi:“MI:0915”(physical association)	0.560
ENC1	SQSTM1	psi-mi:“MI:0403”(colocalization)	0.560
HTT	ENC1	psi-mi:“MI:0914”(association)	0.540
HTT	ENC1	psi-mi:“MI:0915”(physical association)	0.540
ENC1	HTT	psi-mi:“MI:0403”(colocalization)	0.540
ENC1	PLIN5	psi-mi:“MI:0914”(association)	0.530
CAPN2	MYO9A	psi-mi:“MI:0914”(association)	0.530
HSP90AB1	ENC1	psi-mi:“MI:0915”(physical association)	0.400
SPG11	ENC1	psi-mi:“MI:0915”(physical association)	0.370
CUL3	PXDNL	psi-mi:“MI:0914”(association)	0.350
CUL3	KLHL2	psi-mi:“MI:0914”(association)	0.350
ENC1	CUL1	psi-mi:“MI:0914”(association)	0.350
FBXL17	ENC1	psi-mi:“MI:0914”(association)	0.350
BACH2	ENC1	psi-mi:“MI:0914”(association)	0.350
ENC1	IGKC	psi-mi:“MI:0914”(association)	0.350
ACKR3	PDE2A	psi-mi:“MI:0914”(association)	0.350
ALDH3B1	ENC1	psi-mi:“MI:0914”(association)	0.350
BACH1	ENC1	psi-mi:“MI:0914”(association)	0.350
CD80	RIMOC1	psi-mi:“MI:0914”(association)	0.350
CXCR3	RIMOC1	psi-mi:“MI:0914”(association)	0.350
DNAJA2	ENC1	psi-mi:“MI:0914”(association)	0.350

BioGRID (48): ENC1 (Biochemical Activity), SQSTM1 (Affinity Capture-Western), ENC1 (Affinity Capture-Western), KLHL25 (Affinity Capture-MS), ENC1 (Affinity Capture-MS), NUDCD3 (Affinity Capture-MS), PLIN5 (Affinity Capture-MS), ENC1 (Affinity Capture-RNA), ENC1 (Affinity Capture-Western), ENC1 (Affinity Capture-Western), ENC1 (Reconstituted Complex), ENC1 (Affinity Capture-MS), ENC1 (Affinity Capture-MS), NUDCD3 (Affinity Capture-MS), PLIN5 (Affinity Capture-MS)

ESM2 similar proteins: A2AAX3, A2AUC9, B3DIV9, D2HEW7, D3ZA50, D3ZZC3, E9QJ30, G3X9X1, O14682, O35709, O60662, Q08BL9, Q0D2A9, Q1LYM6, Q2TBA0, Q2WGJ6, Q3B7M1, Q4KLM4, Q53GT1, Q56A24, Q5EB39, Q5RCQ9, Q5RDY3, Q5RGB8, Q5U504, Q5U575, Q5ZJU2, Q66HD2, Q6DEL7, Q6DFF7, Q6GQU2, Q6NYM1, Q6Q7X9, Q6TFL4, Q6V595, Q8BRG6, Q8BWA5, Q8CA72, Q8IY47, Q8N4N3

Diamond homologs: A0JMG1, A1YEX3, B0WWP2, B3DIV9, B3M9V8, B3NDN0, B4GRJ2, B4HIK1, B4J045, B4L0G9, B4LIG6, B4MXW3, B4PD06, B4QLQ2, B7U179, D3Z8N4, D4A2K4, E0CZ16, E7F6F9, F1LZF0, F1MBP6, O14682, O22286, O35709, O43791, O81432, O95198, P0DMR5, P0DMR6, P24278, P28575, P34568, P58544, P58545, Q08DK3, Q08DS0, Q0D2A9, Q0IHH9, Q0VCW1, Q16RL8

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 35 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Neddylation	6	12.4×	5e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

40 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	33
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

698 predictions. Top by Δscore:

Variant	Effect	Δscore
5:74637566:TATG:T	donor_gain	1.0000
5:74637567:ATGA:A	donor_gain	1.0000
5:74629988:GTGAG:G	acceptor_gain	0.9900
5:74629989:TGAG:T	acceptor_gain	0.9900
5:74636496:CTC:C	acceptor_gain	0.9900
5:74637563:A:AC	donor_gain	0.9900
5:74637564:C:CC	donor_gain	0.9900
5:74637567:A:AC	donor_gain	0.9900
5:74640305:A:AC	donor_gain	0.9900
5:74640306:C:CC	donor_gain	0.9900
5:74640306:CAG:C	donor_gain	0.9900
5:74629990:GAG:G	acceptor_gain	0.9800
5:74629990:GAGC:G	acceptor_loss	0.9800
5:74629991:AGCTG:A	acceptor_loss	0.9800
5:74629992:GCTG:G	acceptor_loss	0.9800
5:74629993:C:CA	acceptor_loss	0.9800
5:74629993:C:CC	acceptor_gain	0.9800
5:74629994:T:A	acceptor_loss	0.9800
5:74629998:A:AC	acceptor_gain	0.9800
5:74636497:TCC:T	acceptor_loss	0.9800
5:74636499:CTAA:C	acceptor_loss	0.9800
5:74636500:T:A	acceptor_loss	0.9800
5:74631701:A:C	donor_gain	0.9700
5:74634679:CTTA:C	donor_loss	0.9700
5:74634680:TTAC:T	donor_loss	0.9700
5:74634681:T:TA	donor_loss	0.9700
5:74636494:CACTC:C	acceptor_gain	0.9700
5:74636499:C:CC	acceptor_gain	0.9700
5:74640306:CA:C	donor_gain	0.9700
5:74637482:A:C	donor_gain	0.9600

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000043316 (5:74630556 C>T), RS1000055772 (5:74634442 A>G), RS1000085521 (5:74641939 A>C), RS1000152309 (5:74628949 C>G,T), RS1000163647 (5:74628505 A>G), RS1000394207 (5:74638351 A>G), RS1001090845 (5:74640844 G>C), RS1001224357 (5:74642304 A>G), RS1001365894 (5:74629295 G>A), RS1001463162 (5:74633218 C>G,T), RS1001584565 (5:74629679 T>C), RS1001634103 (5:74640890 A>G), RS1002246542 (5:74640891 G>C,T), RS1002322744 (5:74629301 A>G), RS1002371634 (5:74627834 C>A)

Disease associations

OMIM: gene MIM:605173 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST003542_148	Night sleep phenotypes	8.000000e-06
GCST003989_32	Chin dimples	5.000000e-12
GCST004025_5	Systemic juvenile idiopathic arthritis	5.000000e-07
GCST004291_3	Residual cognition	8.000000e-06
GCST006444_15	Bone mineral density (hip)	5.000000e-06

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0003925	cognition
EFO:0022597	aging
EFO:0007702	hip bone mineral density

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

107 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	affects expression, affects cotreatment, decreases expression, increases expression	5
Valproic Acid	affects expression, decreases expression, decreases methylation, increases expression	5
Cyclosporine	affects cotreatment, decreases expression	5
bisphenol A	affects expression, decreases expression	4
trichostatin A	affects methylation, increases expression, affects cotreatment, affects expression	4
sodium arsenite	affects methylation, decreases expression, increases abundance, increases expression	4
Resveratrol	affects cotreatment, decreases expression, increases expression	4
Tretinoin	decreases expression, increases expression	4
Aflatoxin B1	affects expression, increases expression, increases methylation	4
Benzo(a)pyrene	increases expression, increases methylation	3
Formaldehyde	decreases expression, increases expression	3
methylmercuric chloride	increases expression	2
Vorinostat	decreases expression, increases expression	2
Acetaminophen	decreases expression, increases expression	2
Doxorubicin	increases expression	2
Ethinyl Estradiol	decreases expression, affects expression	2
Hydrogen Peroxide	affects expression, increases expression	2
Lipopolysaccharides	affects expression, affects cotreatment, decreases expression, affects reaction	2
Progesterone	affects cotreatment, decreases expression	2
Silicon Dioxide	increases expression	2
Tamoxifen	increases expression, affects expression, affects cotreatment, decreases expression	2
Tunicamycin	decreases expression	2
Raloxifene Hydrochloride	decreases expression, increases expression, affects expression, affects cotreatment	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
GSK-J4	increases expression	1
3,19-(2-bromobenzylidene)andrographolide	decreases expression, decreases response to substance	1
urushiol	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	decreases expression, increases abundance, affects cotreatment	1
pirinixic acid	affects binding, decreases expression, increases activity	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.